


Amendments to the Claims

1-71. (Canceled).

72. (Currently amended) A compound having the structural formula (A),



wherein:

- the dotted lines represent an optional double bond, provided that no two double bonds are adjacent to one another, and that the dotted lines represent at least 3, optionally 4 double bonds;
- R¹ is selected from the group consisting of hydrogen, aryl, heterocycle, C₁-C₁₀ alkoxy, C₁-C₁₀ thioalkyl, C₁-C₁₀ alkyl-amino, C₁-C₁₀ dialkylamino, C₃-C₁₀ cycloalkyl, C₄-C₁₀ cycloalkenyl, and C₄-C₁₀ cycloalkynyl, wherein each is optionally substituted with one or more R⁶;
- Y is selected from a single bond, O, S(O)_m, NR¹¹, C₁-C₁₀ alkylene, C₂-C₁₀ alkenylene, or C₂-C₁₀ alkynylene, wherein each alkylene, alkenylene or alkynylene optionally includes 1 to 3 heteroatoms selected from O, S or N; provided that YR¹ is not hydrogen or C₁-C₆-alkyl;
- R² and R⁴ are independently selected from the group consisting of hydrogen, C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl, C₂-C₁₈ alkynyl, C₁-C₁₈ alkoxy, C₁-C₁₈ alkylthio, halogen, -OH, -CN, -NO₂, -NR⁷R⁸, haloalkyloxy, haloalkyl, -C(=O)R⁹, -C(=S)R⁹, -SH, aryl, aryloxy, arylthio, arylalkyl, C₁-C₁₈ hydroxyalkyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkyloxy, C₃-C₁₀ cycloalkylthio, C₃-C₁₀ cycloalkenyl, C₇-C₁₀ cycloalkynyl, or

and heterocycle, provided that or when one of R²⁵ or R²⁶ is present, then either R² or R⁴ is selected from the group consisting of (=O), (=S), and =NR²⁷;


- X is selected from the group consisting of C₁-C₁₀ alkylene, C₂-₁₀ alkenylene or and C₂-₁₀ alkynylene, where each optionally includes one or more heteroatoms selected from the group consisting of O, S, or N, provided any such heteroatom is not adjacent to the N in the imidazopyridyl ring;
- m is any integer from 0 to 2;
- R³ is a heterocycle substituted with one or more R¹⁷, provided that R³ optionally substituted with at least one R¹⁷ is not pyridinyl or 5-chlorothienyl;
- R⁵ is selected from the group consisting of hydrogen, C₁-₁₈ alkyl, C₂-₁₈ alkenyl, C₂-₁₈ alkynyl, C₁-₁₈ alkoxy, C₁-₁₈ alkylthio, halogen, -OH, -CN, -NO₂, -NR⁷R⁸, haloalkyloxy, haloalkyl, -C(=O)R⁹, -C(=O)OR⁹, -C(=S)R⁹, SH, aryl, aryloxy, arylthio, arylalkyl, C₁-₁₈ hydroxyalkyl, C₃-₁₀ cycloalkyl, C₃-₁₀ cycloalkyloxy, C₃-₁₀ cycloalkylthio, C₃-₁₀ cycloalkenyl, C₇-₁₀ cycloalkynyl, or and heterocycle;
- each R⁶ is independently selected from the group consisting of hydrogen, C₁-₁₈ alkyl, C₂-₁₈ alkenyl, C₂-₁₈ alkynyl, C₁-₁₈ alkoxy, C₁-₁₈ alkylthio, C₁-₁₈ alkylsulfoxide, C₁-₁₈ alkylsulfone, C₁-₁₈ halo-alkyl, C₂-₁₈ halo-alkenyl, C₂-₁₈ halo-alkynyl, C₁-₁₈ halo-alkoxy, C₁-₁₈ halo-alkylthio, C₃-₁₀ cycloalkyl, C₃-₁₀ cycloalkenyl, C₇-₁₀ cycloalkynyl, halogen, -OH, -CN, cyanoalkyl, -CO₂R¹⁸, -NO₂, -NR⁷R⁸, C₁-₁₈ haloalkyl, -C(=O)R¹⁸, -C(=S)R¹⁸, -SH, aryl, aryloxy, arylthio, arylsulfoxide, arylsulfone, arylsulfonamide, aryl(C₁-₁₈)alkyl, aryl(C₁-₁₈)alkyloxy, aryl(C₁-₁₈)alkylthio, heterocycle and C₁-₁₈ hydroxyalkyl, where each is optionally substituted with one or more R¹⁹;
- R⁷ and R⁸ are independently selected from the group consisting of hydrogen, C₁-₁₈ alkyl, C₁-₁₈ alkenyl, aryl, C₃-₁₀ cycloalkyl, C₄-₁₀ cycloalkenyl, heterocycle, -C(=O)R¹²; -C(=S)R¹², and an amino acid residue linked through a carboxyl group thereof, or R⁷ and R⁸ are taken together with the nitrogen to form a heterocycle;


- R^9 and R^{18} are independently selected from the group consisting of hydrogen, -OH, C_{1-18} alkyl, C_{2-18} alkenyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, C_{1-18} alkoxy, $-NR^{15}R^{16}$, aryl, an amino acid residue linked through an amino group of the amino acid, $-\text{CH}_2\text{OCH}(=\text{O})\text{R}^{9a}$, or and $-\text{CH}_2\text{OC}(=\text{O})\text{OR}^{9a}$ where R^{9a} is $C_{1-C_{12}}$ alkyl, $C_6\text{-C}_{20}$ aryl, $C_6\text{-C}_{20}$ alkylaryl or $C_6\text{-C}_{20}$ aralkyl;
- R^{10} and R^{11} are independently is selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, aryl, $-\text{C}(=\text{O})\text{R}^{12}$, heterocycle, or and an amino acid residue;
- R^{12} is selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, aryl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, or and an amino acid residue;
- R^{15} and R^{16} are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, aryl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, or and an amino acid residue;
- each R^{17} is independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, C_{1-18} alkoxy, C_{1-18} alkylthio, C_{1-18} alkylsulfoxide, C_{1-18} alkylsulfone, C_{2-18} halogenated alkenyl, C_{2-18} halogenated alkynyl, C_{2-18} halogenated alkoxy, C_{1-18} halogenated alkylthio, C_{3-10} cycloalkyl, C_{3-10} cycloalkenyl, C_{7-10} cycloalkynyl, halogen, OH, CN, NO_2 , NR^7R^8 , haloalkyl, $\text{C}(=\text{O})\text{R}^{18}$, $\text{C}(=\text{S})\text{R}^{18}$, SH, aryl, aryloxy, arylthio, CO_2H , CO_2R^{18} , arylsulfoxide, arylsulfone, arylsulfonamide, arylalkyl, arylalkyloxy, arylalkylthio, heterocyclic, and C_{1-18} hydroxyalkyl, where each of said aryl, aryloxy, arylthio, arylalkyl, arylalkyloxy, arylalkylthio, heterocycle, C_{1-18} hydroxyalkyl, arylsulfoxide, arylsulfone, or arylsulfonamide is optionally substituted with one or more R^{19} ;
- each R^{19} is independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, C_{1-18} alkoxy, C_{2-18} alkenyloxy, C_{2-18} alkynyoxy, C_{1-18} alkylthio, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, C_{1-18} cycloalkynyl, halogen, -OH, -CN, cyanoalkyl, $-\text{NO}_2$, $-\text{NR}^{20}\text{R}^{21}$, C_{1-18} haloalkyl, C_{1-18} haloalkyloxy, $-\text{C}(=\text{O})\text{R}^{18}$, $-\text{C}(=\text{O})\text{OR}^{18}$, -OalkenylC(=O)OR¹⁸,

- $\text{-OalkylC(=O)NR}^{20}\text{R}^{21}$, $\text{-OalkylOC(=O)R}^{18}$, -C(=S)R^{18} , SH , $\text{-C(=O)N(C}_{1-6}\text{ alkyl)}$, $\text{-N(H)S(O)(O)(C}_{1-6}\text{ alkyl)}$, aryl, heterocycle, C_{1-18} alkylsulfone, arylsulfoxide, arylsulfonamide, $\text{aryl(C}_{1-18}\text{)alkyloxy}$, aryloxy , $\text{aryl(C}_{1-18}\text{)alkyl}$, arylthio , $\text{aryl(C}_{1-18}\text{)alkylthio}$ or and $\text{aryl(C}_{1-18}\text{)alkyl}$, where each is optionally substituted with 1 or more $=\text{O}$, $\text{-NR}^{20}\text{R}^{21}$, -CN , C_{1-18} alkoxy, heterocycle, C_{1-18} haloalkyl, heterocycle alkyl, heterocycle connected to R^{17} by alkyl, alkoxyalkoxy or halogen;
- R^{20} and R^{21} are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, aryl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, -C(=O)R^{12} , carboxylester-substituted heterocycle, or and -C(=S)R^{12} ;
 - R^{25} and R^{26} are not present, or are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{3-10} cycloalkyl, aryl and heterocycle, where each is optionally independently substituted with 1 to 4 of C_{1-6} alkyl, C_{1-6} alkoxy, halo, $\text{-CH}_2\text{OH}$, benzyloxy, and -OH ; and
 - R^{27} is selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{3-10} cycloalkyl, $(\text{C}_{3-10}$ cycloalkyl)- C_{1-6} alkyl, aryl, and $\text{aryl(C}_{1-18}\text{)alkyl}$; and salts, tautomers, and stereoisomers and solvates thereof.

73. – 78. (Cancelled)

79. (Currently amended) A compound having the structural formula (C) (A)





wherein:

- the dotted lines represent an optional double bond, provided that no two double bonds are adjacent to one another, and that the dotted lines represent at least 3, optionally 4 double bonds;
- R^1 is selected from the group consisting of hydrogen, aryl, heterocycle, $C_{1-C_{10}}$ alkoxy, $C_{1-C_{10}}$ thioalkyl, $C_{1-C_{10}}$ alkyl-amino, $C_{1-C_{10}}$ dialkylamino, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, and C_{4-10} cycloalkynyl, wherein each are is optionally substituted with one or more R^6 ;
- Y is selected from a single bond, O, $S(O)_m$, NR^{11} , C_{1-10} alkylene, C_{2-10} alkenylene, or C_{2-10} alkynylene, wherein each alkylene, alkenylene or alkynylene optionally includes 1 to 3 heteroatoms selected from O, S or N; provided that YR^4 is not hydrogen or C_{4-6} alkyl;
- R^2 and R^4 are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, C_{1-18} alkoxy, C_{1-18} alkylthio, halogen, -OH, -CN, $-NO_2$, $-NR^7R^8$, haloalkyloxy, haloalkyl, $-C(=O)R^9$, $-C(=S)R^9$, -SH, aryl, aryloxy, arylthio, arylalkyl, C_{1-18} hydroxyalkyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyloxy, C_{3-10} cycloalkylthio, C_{3-10} cycloalkenyl, C_{7-10} cycloalkynyl, or and heterocycle, provided that when one of R^{25} or R^{26} is present, then either R^2 or R^4 is selected from the group consisting of $(=O)$, $(=S)$, and $=NR^{27}$;
- X is selected from the group consisting of $C_{1-C_{10}}$ alkylene, C_{2-10} alkenylene or and C_{2-10} alkynylene, where each optionally includes one or more heteroatoms

selected from the group consisting of O, S, or N, provided any such heteroatom is not adjacent to the N in the imidazopyridyl ring;

- m is any integer from 0 to 2;
- R³ is a 4-, 7-, 8- or 9-membered aryl, aryloxy, arylthio, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl-N(R¹⁰)-, or heterocycle, each of which is optionally substituted with one or more R¹⁷, provided that for cycloalkenyl the double bond is not adjacent to a nitrogen, provided M-Q-R³ is not biphenyl, and provided that R³ substituted with at least one R¹⁷ is not pyridinyl or 5-chlorothienyl;
- R⁵ is selected from the group consisting of hydrogen, C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, C₂₋₁₈ alkynyl, C₁₋₁₈ alkoxy, C₁₋₁₈ alkylthio, halogen, -OH, -CN, -NO₂, -NR⁷R⁸, haloalkyloxy, haloalkyl, -C(=O)R⁹, -C(=O)OR⁹, -C(=S)R⁹, -SH, aryl, aryloxy, arylthio, arylalkyl, C₁₋₁₈ hydroxyalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ cycloalkyloxy, C₃₋₁₀ cycloalkylthio, C₃₋₁₀ cycloalkenyl, C₇₋₁₀ cycloalkynyl, or and heterocycle;
- each R⁶ is independently selected from the group consisting of hydrogen, C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, C₂₋₁₈ alkynyl, C₁₋₁₈ alkoxy, C₁₋₁₈ alkylthio, C₁₋₁₈ alkylsulfoxide, C₁₋₁₈ alkylsulfone, C₁₋₁₈ halo-alkyl, C₂₋₁₈ halo-alkenyl, C₂₋₁₈ halo-alkynyl, C₁₋₁₈ halo-alkoxy, C₁₋₁₈ halo-alkylthio, C₃₋₁₀ cycloalkyl, C₃₋₁₀ cycloalkenyl, C₇₋₁₀ cycloalkynyl, halogen, -OH, -CN, cyanoalkyl, -CO₂R¹⁸, -NO₂, -NR⁷R⁸, C₁₋₁₈ haloalkyl, -C(=O)R¹⁸, -C(=S)R¹⁸, -SH, aryl, aryloxy, arylthio, arylsulfoxide, arylsulfone, arylsulfonamide, aryl(C₁₋₁₈)alkyl, aryl(C₁₋₁₈)alkyloxy, aryl(C₁₋₁₈)alkylthio, heterocycle and C₁₋₁₈ hydroxyalkyl, where each is optionally substituted with one or more R¹⁹;
- R⁷ and R⁸ are independently selected from the group consisting of hydrogen, C₁₋₁₈ alkyl, C₁₋₁₈ alkenyl, aryl, C₃₋₁₀ cycloalkyl, C₄₋₁₀ cycloalkenyl, heterocycle, -C(=O)R¹²; -C(=S)R¹², and an amino acid residue linked through a carboxyl group thereof, or R⁷ and R⁸ are taken together with the nitrogen to form a heterocycle;

- R^9 and R^{18} are independently selected from the group consisting of hydrogen, -OH, C_{1-18} alkyl, C_{2-18} alkenyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, C_{1-18} alkoxy, $-NR^{15}R^{16}$, aryl, an amino acid residue linked through an amino group of the amino acid, $-CH_2OCH(=O)R^{9a}$, or and $-CH_2OC(=O)OR^{9a}$ where R^{9a} is C_1-C_{12} alkyl, C_6-C_{20} aryl, C_6-C_{20} alkylaryl or C_6-C_{20} aralkyl;
- R^{10} and R^{11} are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, aryl, $-C(=O)R^{12}$, heterocycle, or and an amino acid residue;
- R^{12} is selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, aryl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, or and an amino acid residue;
- R^{15} and R^{16} are independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, aryl, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, or and an amino acid residue;
- each R^{17} is independently $MQ-$ wherein M is a ring optionally substituted with one or more R^{19} , and Q is a bond or a linking group connecting M to R^3 that has 1 to 10 atoms and is optionally substituted with one or more R^{19} ;
- each R^{19} is independently selected from the group consisting of hydrogen, C_{1-18} alkyl, C_{2-18} alkenyl, C_{2-18} alkynyl, C_{1-18} alkoxy, C_{2-18} alkenyloxy, C_{2-18} alkynyoxy, C_{1-18} alkylthio, C_{3-10} cycloalkyl, C_{4-10} cycloalkenyl, C_{4-10} cycloalkynyl, halogen, $-OH$, $-CN$, cyanoalkyl, $-NO_2$, $-NR^{20}R^{21}$, C_{1-18} haloalkyl, C_{1-18} haloalkyloxy, $-C(=O)R^{18}$, $-C(=O)OR^{18}$, $-OalkenylC(=O)OR^{18}$, $-OalkylC(=O)NR^{20}R^{21}$, $-OalkylOC(=O)R^{18}$, $-C(=S)R^{18}$, $-SH$, $-C(=O)N(C_{1-6}alkyl)$, $-N(H)S(O)(O)(C_{1-6}alkyl)$, aryl, heterocycle, C_{1-18} alkylsulfone, arylsulfoxide, arylsulfonamide, $aryl(C_{1-18})alkyloxy$, $aryloxy$, $aryl(C_{1-18})alkyloxy$, arylthio, $aryl(C_{1-18})alkylthio$ or $aryl(C_{1-18})alkyl$, where each is optionally substituted with 1 or more $=O$, $-NR^{20}R^{21}$, $-CN$, C_{1-18} alkoxy, heterocycle, C_{1-18} haloalkyl, heterocycle alkyl, heterocycle connected to R^{17} by alkyl, alkoxyalkoxy or and halogen;

- R²⁰ and R²¹ are independently selected from the group consisting of hydrogen, C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, C₂₋₁₈ alkynyl, aryl, C₃₋₁₀ cycloalkyl, C₄₋₁₀ cycloalkenyl, -C(=O)R¹², or -C(=S)R¹²;
- R²⁵ and R²⁶ are not present, or are independently selected from the group consisting of hydrogen, C₁₋₁₈ alkyl, C₃₋₁₀ cycloalkyl, aryl and heterocycle, where each is optionally independently substituted with 1 to 4 of C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, -CH₂OH, benzyloxy, and -OH; and
- R²⁷ is selected from the group consisting of hydrogen, C₁₋₁₈ alkyl, C₃₋₁₀ cycloalkyl, (C₃₋₁₀ cycloalkyl)-C₁₋₆ alkyl, aryl, and aryl(C₁₋₁₈)alkyl; and salts, tautomers, and stereoisomers and solvates thereof.

80. (Cancelled)

81. (Currently amended) A compound according to claim 72, wherein R³ is isoxazolyl substituted with one to three R¹⁷.

82.-85. (Cancelled)

86. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound according to claim 72.

87. -89. (Cancelled)

90. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound according to claim 79.

91. (New) The compound of claim 72, wherein YR¹ is halophenyl or halomethyl-substituted phenyl.

92. (New) The compound of claim 91, wherein halophenyl is ortho-fluorophenyl.

93. (New) The compound of claim 72, wherein R¹⁷ is aryl or a heterocycle further substituted with 1, 2 or 3 R¹⁹.

94. (New) The compound of claim 72, wherein YR¹ is not an unsubstituted C₃₋₁₀ cycloalkyl.

95. (New) The compound of claim 72 wherein R¹⁹ is trihalomethyl, trihalomethoxy, alkoxy or halogen.

96. (New) The compound of claim 72, wherein R¹ is aryl or aromatic heterocycle substituted with 1, 2 or 3 R⁶ and wherein R⁶ is halogen, C₁₋₁₈ alkoxy or C₁₋₁₈ haloalkyl.

97. (New) The compound of claim 72, wherein Y is a bond.

98. (New) The compound of claim 72, wherein X is selected from the group consisting of -CH₂-, -CH(CH₃)-, -CH₂-CH₂-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-, -(CH₂)₂₋₄-O-(CH₂)₂₋₄-, -(CH₂)₂₋₄-S-(CH₂)₂₋₄-, -(CH₂)₂₋₄-NR¹⁰-(CH₂)₂₋₄-, C₃₋₁₀ cycloalkylidene, C₂₋₆ alkenylene and C₂₋₆ alkynylene, wherein R¹⁰ is selected from the group consisting of hydrogen, C₁₋₁₈ alkyl, C₂₋₁₈ alkenyl, C₃₋₁₀ cycloalkyl, C₄₋₁₀ cycloalkenyl, aryl, -C(=O)R¹², heterocyclic, and an amino acid residue.

99. (New) The compound of claim 72, wherein X is methylene.

100. (New) The compound of claim 72, wherein R³ is a heterocycle substituted with 0 to 3 R¹⁷.

101. (New) The compound of claim 100, wherein the R³ is an aromatic heterocycle.

102. (New) The compound of claim 101, wherein the heterocycle contains 1, 2 or 3 N, S or O atoms in the ring, is linked to X through a ring carbon atom and contains 4 to 6 total ring atoms.

103. (New) The compound of claim 72, wherein R¹⁷ is selected from the group consisting of C₃₋₁₀ cycloalkyl, C₃₋₁₀ cycloalkenyl, C₇₋₁₀ cycloalkynyl, aryl, aryloxy, arylthio, arylsulfoxide, arylsulfone, arylsulfonamide, arylalkyl; arylalkyloxy; arylalkylthio and heterocycle, each being unsubstituted or substituted with 1 or more R¹⁹.

104. (New) The compound of claim 72, wherein R⁹ and R¹⁸ are H, OH or alkyl.

105. (New) The compound of claim 72, wherein R⁵ is H.

106. (New) The compound of claim 72, wherein R⁶ is halogen.

107. (New) The compound of claim 72, wherein R⁷, R⁸, R¹¹, R¹⁵, R¹⁶, R²⁰, and R²¹ are independently H or C₁₋₁₈ alkyl.

108. (New) The compound of claim 72, wherein R¹² is OH or alkyl.

109. (New) The compound of claim 72, wherein R¹⁹ is selected from the group consisting of H; C₁₋₁₈ alkyl; C₂₋₁₈ alkenyl; C₂₋₁₈ alkynyl; C₁₋₁₈ alkoxy; alkenyloxy; alkynyloxy; C₁₋₁₈ alkylthio; C₃₋₁₀ cycloalkyl; C₄₋₁₀ cycloalkenyl; C₄₋₁₀

cycloalkynyl; halogen; OH; CN; cyanoalkyl; NO_2 ; $\text{NR}^{20}\text{R}^{21}$; haloalkyl; haloalkyloxy; $\text{C}(=\text{O})\text{R}^{18}$; $\text{C}(=\text{O})\text{OR}^{18}$; OalkenylC(=O)OR¹⁸; -OalkylC(=O)NR²⁰R²¹; aryl; heterocycle; -OalkylOC(=O)R¹⁸; C(=O)N(C₁₋₆ alkyl), N(H)S(O)(O)(C₁₋₆ alkyl); arylalkyloxy; aryloxy; arylalkyloxy; and arylalkyl; each of which is unsubstituted or substituted with 1 or more =O; $\text{NR}^{20}\text{R}^{21}$; CN; alkoxy; heterocycle; haloalkyl- or alkyl-substituted heterocycle; and heterocycle linked to R¹⁷ by alkyl; alkoxyalkoxy and halogen.

110. (New) The compound of claim 109, wherein R¹⁹ is independently selected from the group consisting of halogen, $\text{NR}^{20}\text{R}^{21}$, alkoxy, halo-substituted alkyl and halo-substituted alkoxy.

111. (New) The compound of claim 72, wherein R²⁵ and R²⁶ are not present.

112. (New) The compound of claim 72, wherein haloalkyl or haloalkyloxy is -CF₃ or -OCF₃.

113. (New) The compound of claim 72, wherein Y is a single bond, and R¹ is phenyl.

114. (New) The compound of claim 79, wherein Y is a single bond, and R¹ is aryl.

115. (New) The compound of claim 79, wherein X is C₁-C₁₀ alkylene, C₂₋₁₀ alkenylene or C₂₋₁₀ alkynylene.

116. (New) The compound of claim 79, wherein R³ is a heterocycle.

117. (New) The compound of claim 79, wherein R³ is a heterocycle substituted with R¹⁷ where Q is a bond and M is aryl.

118. (New) The compound of claim 79, wherein R³ is isoxazole substituted with R¹⁷ where Q is a bond and M is aryl.

119. (New) A method comprising administering to a subject in need of treatment or prophylaxis of a viral infection an anti-virally effective amount of a compound of claim 72 or claim 79.

120. (New) The method of claim 119, wherein the viral infection is an infection of a hepatitis-C virus.

121. (New) The method of claim 119, further comprising administering at least one additional antiviral therapy to the subject.

122. (New) The method of claim 121 wherein the additional therapy is selected from the group consisting of an interferon alpha and ribavirin.

123. (New) The method of claim 119, wherein the viral infection is an infection from a virus belonging to the family of the Flaviridae and the Picornaviridae.

124. (New) The method of claim 119, wherein the viral infection is an infection from a Coxsackie virus.

125. (New) The method of claim 119, wherein the viral infection is an infection from a Bovine Viral Diarrhea Virus.